ERBB2 and breast cancer: For example, a standard therapy for HER2-positive breast cancer is the anti-HER2 antibody trastuzumab, whose main mechanism of action is through antibody-dependent cellular cytotoxicity by interacting with Fc receptors, such as CD16 expressed on NK cells [49–51].